DVA compared with MGRX: revenue, margins and what each company keeps, and the suppliers and customers both name

DVADaVita Inc.

Mkt capRevenueRevenue

MGRXMangoceuticals, Inc.

Mkt capRevenueRevenue

Compare

DVADaVita Inc.

MGRXMangoceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

DVA

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±10.1%▼−3.01%×0.30

Q2 FY26±10.8%▼−17.24%×1.59

Q1 FY26±8.9%▲+23.46%×2.64

Feb 3 '26±8.1%▲+21.17%×2.62

MGRX

No earnings history for MGRX.

= impliedDVA realized, solidMGRX realized, hatchedOne scale, both sides: full bar = 24%× = |realized| ÷ impliedSource: market data

DVADaVita Inc.

190.80▼−2.06%· post 192.00

Mkt cap$12.0BRevenue$3.6BQ3 FY26Revenue$13.6BFY25

MGRXMangoceuticals, Inc.

0.20▲+4.33%· post 0.20

ClosedNov 6 '26

Mkt cap$4.2MRevenue$68,757Q2 FY26Revenue$456,021FY25

Compare

ClosedNov 6 '26

DVADaVita Inc.

MGRXMangoceuticals, Inc.

190.80▼−2.06%post 192.00

Price

0.20▲+4.33%post 0.20

$12.0B

Mkt cap

$4.2M

Q3 FY26$3.6B

Revenue

$68,757Q2 FY26

FY25$13.6B

Revenue

$456,021FY25

DVA190.80▼−2.06%vsMGRX0.20▲+4.33%ClosedNov 6 '26